Recombinant Human GCDH Protein，His

GCDH (Glutaryl-CoA Dehydrogenase) is a crucial enzyme involved in the catabolism of lysine, hydroxylysine, and tryptophan, playing a significant role in the metabolic pathway that converts these amino acids into acetoacetate and acetyl-CoA. Mutations in the GCDH gene lead to glutaryl-CoA dehydrogenase deficiency (GCDH deficiency), a rare but severe metabolic disorder characterized by the accumulation of toxic metabolites, resulting in neurological impairment, movement disorders, and metabolic crises. The incidence of GCDH deficiency varies globally, with a particularly high prevalence in certain populations, emphasizing the need for effective diagnostic and therapeutic strategies. Research on GCDH recombinant proteins has gained traction as it provides insights into enzyme function, structure, and potential therapies. Producing GCDH as a recombinant protein allows for better understanding of its catalytic mechanisms, substrate interactions, and the impact of specific mutations associated with the deficiency. Furthermore, recombinant GCDH has the potential for therapeutic applications, including enzyme replacement therapy and development of small molecules to restore enzyme activity in affected individuals. The advancement of protein engineering techniques and high-throughput screening methods presents new avenues for developing effective treatments, enhancing our understanding of the disease, and addressing the metabolic imbalance in patients. Thus, GCDH recombinant protein research stands at the intersection of fundamental biochemistry and clinical application, representing a hopeful frontier in the fight against inherited metabolic disorders.